InvestorsHub Logo
Followers 0
Posts 1444
Boards Moderated 0
Alias Born 03/19/2012

Re: None

Thursday, 07/25/2013 7:21:48 AM

Thursday, July 25, 2013 7:21:48 AM

Post# of 401900
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation


Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.
"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline," said Jerry Treppel, Elite's Chairman and CEO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News